1
Home
Companies

BioAtla

#9882

Rank

$23.89M

Marketcap

US United States

Country

BioAtla
Leadership team

Dr. Jay M. Short Ph.D. (Co-Founder, CEO & Chairman)

Mr. Scott Andrew Smith (Pres & Director)

Mr. Richard A. Waldron (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
San Diego, California, United States
Established
2007
Company Registration
SEC CIK number: 0001826892
Traded as
BCAB
Social Media
URL
https://www.bioatla.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
History

BioAtla was founded in 2009 by renowned scientist and immunotherapy developer Laurent Thisse and venture capitalist Iain Howlett. Their mission was to develop innovative, safe, and effective treatments for a range of chronic and life-threatening illnesses. Since its founding, BioAtla has recruited renowned scientists and executives to build a powerful team of innovators and pioneers. Together, the company has developed a range of immunotherapy technologies designed to target and treat specific diseases.

Mission
BioAtla is committed to advancing healthcare through the development of breakthrough treatments for cancer and other serious diseases.
Vision
BioAtla seeks to be a trusted partner in developing treatments that save lives and improve patient outcomes.
Key Team

Dr. Eric L. Sievers M.D. (Chief Medical Officer)

Ms. Monica Sullivan (Sr. VP of Intellectual Property & Contracts)

Mr. Christian Vasquez (VP of Fin., Corp. Controller & Sec.)

Dr. Cathy Chang Ph.D. (Sr. VP of R&D)

Mr. Philippe Martin (Chief Clinical Devel. & Operations)

Lisa M. Pelton (Accounting Mang.)

Ms. Susie Melody (Sr. VP of HR)

Recognition and Awards
BioAtla has been widely recognized for its leadership in breakthrough treatments, with awards including the National Institutes of Health Award for Excellence in Science and Technology and the Biotech Industry Award for best New Product and Innovation Development.
References

https://in.investing.com/equities/bioatla

https://finance.yahoo.com/quote/BCAB/profile?p=BCAB

https://www.crunchbase.com/organization/bioatla

https://companiesmarketcap.com/

https://www.bioatla.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

BioAtla
Leadership team

Dr. Jay M. Short Ph.D. (Co-Founder, CEO & Chairman)

Mr. Scott Andrew Smith (Pres & Director)

Mr. Richard A. Waldron (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
San Diego, California, United States
Established
2007
Company Registration
SEC CIK number: 0001826892
Traded as
BCAB
Social Media
URL
https://www.bioatla.com